Date: 2012-12-05
Type of information: Production agreement
Compound: development and manufacturing services for APX005, a humanized monoclonal antibody targeting CD40 for the treatment of cancers
Company: Apexigen (USA) Boehringer Ingelheim (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: manufacturing
production
Action mechanism:
Disease: cancers
Details: Boehringer Ingelheim Biopharmaceuticals and Apexigen, an emerging biopharmaceutical company dedicated to the discovery and development of best-in-class therapeutic monoclonal antibodies, have announced the signing of a manufacturing supply agreement. As part of the agreement Boehringer Ingelheim will provide cell line development with the high expression BI-HEX® system, full process and method development, scale-up and clinical phase I supply including fill & finish development for APX005, a humanized monoclonal antibody targeting CD40 for the treatment of cancers. APX005 is a strong CD40 agonist that has exhibited potent anti-tumor activities in preclinical studies.
Financial terms:
Latest news:
